Insider · CIK 0001474056
Thomas J. Lynch Jr.
Files at NTRA (Natera, Inc.), FHTX (Foghorn Therapeutics Inc.). First filing -, latest -.
In brief
Thomas J. Lynch Jr. files SEC Form 4 as director at NTRA (Natera, Inc.), and also at FHTX (Foghorn Therapeutics Inc.). No open-market trade is on file; the transactions below are grants, exercises and other rows that carry no view on the price.
A track record needs three past buys with six months of prices behind them; Thomas J. Lynch Jr. has 0, so none is measured yet.
Signals
This insider’s open-market buys and sells, scored.
Transactions
Every row this insider has filed, 3 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jun 26, 2026 | NTRA Natera, Inc. | AGrant or award Common Stock | +1,905 | - | - | 1,905 | Jun 30, 2026 |
| Jun 24, 2026 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Options (Right to buy)derivative | +28,000 | $4.08 | $114k | 28,000 | Jun 25, 2026 |
| Jun 17, 2025 | FHTX Foghorn Therapeutics Inc. | AGrant or award Stock Option (right to buy)derivative | +25,000 | $4.79 | $120k | 25,000 | Jun 17, 2025 |
Questions about Thomas J. Lynch Jr.
Answered from the filings on this page, as of the latest one.
Is Thomas J. Lynch Jr. buying or selling?
Thomas J. Lynch Jr. has no open-market buy or sell on SEC Form 4; the filings on record are grants, exercises and other transactions.
How did Thomas J. Lynch Jr.'s past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Thomas J. Lynch Jr. has 0.
Where does Thomas J. Lynch Jr. file Form 4?
Thomas J. Lynch Jr. has filed Form 4 at NTRA (Natera, Inc.); FHTX (Foghorn Therapeutics Inc.). A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.